Andy Goren

Prof. Andy Goren has over 25 years of experience in research, development, and commercialization of breakthrough therapeutics and diagnostics. Among the list of many firsts in dermatology, Prof. Goren was the first to develop a clinical genetic test for predicting androgenetic alopecia, the first to discover epigenetic markers predicting anti-androgen therapy response in female androgenetic alopecia, the first to develop a clinical acne vulgaris antibiotic response test based on P. Acnes bacterial genomics, and the first to develop a rapid test for predicting minoxidil response in androgenetic alopecia. Prof. Goren was involved in the development, commercialization, and listing of several drugs and medical devices including new therapies for female pattern hair loss, chemotherapy-induced alopecia, excessive hair shedding, female sexual dysfunction, and COVID-19. His latest research is focused on human adaptation to the energy crisis. Prof. Goren currently serves as an External Medical Advisor and a Co-Researcher at the Trichology Unit, Ramon y Cajal Hospital, Madrid, Spain; a Visiting Professor of Dermatology at the Department of Dermatology and Venereology, Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia; a Medical Doctor at the Skin & Cosmetic Research Dept., Shanghai Skin Disease Hospital, Shanghai, China; and a Visiting Medical Doctor at the Department of Dermatology and Venereology, L.T.M. Medical College Sion, Mumbai, India. As the Clinical Research Director at Samel Hospital, Manaus, Brazil, Prof. Goren has published dozens of peer-reviewed original medical research papers. He is an honorary as well as ordinary member of several dermatology societies worldwide as well as a regular lecturer at dermatology congresses around the world. He has had numerous appearances and interviews on TV, radio, and in prestigious newspapers.